Table 2. Univariate and multivariate survival analysis of factors associated with survival.
| Factors | DFS | ||
|---|---|---|---|
| Univariate (P value) | Multivariate | ||
| P value | Hazard ratio (95% CI) | ||
| Age (<40 vs. ≥40 years) | 0.564 | 0.757 | – |
| Menopausal status (pre vs. post) | 0.803 | 0.305 | – |
| Initial tumor status (T2 vs. T3 vs. T4) | 0.028 | 0.067 | – |
| Residual tumor size (≤2 vs. 2–5 vs. >5 cm) | 0.286 | 0.303 | – |
| Residual involved nodes (0 vs. 1–3 vs. ≥4) | <0.001 | <0.001 | 1.000 |
| 2.344 (0.898–6.118) | |||
| 4.427 (1.890–10.370) | |||
| HR* status (negative vs. positive) | 0.412 | 0.912 | – |
| Vascular invasion (negative vs. positive) | 0.186 | 0.532 | – |
| Grade (I–II vs. III) | 0.885 | 0.580 | – |
| Ki-67 (low vs. high) | 0.011 | 0.005 | 1.968 (1.231–3.144) |
| eEF2K (− vs. + vs. ++) | 0.002 | 0.027 | 1.000 |
| 1.668 (0.860–3.234) | |||
| 2.156 (1.209–3.846) | |||
| LC3 (− vs. + vs. ++) | 0.002 | 0.001 | 1.000 |
| 2.156 (1.128–4.119) | |||
| 3.114 (1.675–5.788) | |||
*, HR-positive was defined as ER- and/or PR-positive, HR-negative was defined as ER-negative and PR-negative. DFS, disease-free survival; CI, confidence interval; HR, hormone receptor; eEF2K, eukaryotic elongation factor 2 kinase; ER, estrogen receptor; PR, progesterone receptor.